公开(公告)号：EP3059236A1

公开(公告)日：2016-08-24

申请号：EP15305274.1

申请日：2015-02-23

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  Institut Curie ,  UNIVERSITE DE MONTPELLIER

发明人： Scherrer, Didier ,  Garcel, Aude ,  Campos, Noelie ,  Tazi, Jamal ,  Vautrin, Audrey ,  Mahuteau, Florence ,  Najman, Romain ,  Fornarelli, Pauline

IPC分类号： C07D405/12

CPC分类号： C07H17/02 ,  C07D405/12

摘要： The present invention relates to a quinoline derivative of formula (1)

or one of its pharmaceutically acceptable salts.
The present invention further relates to said quinoline derivative for use as a medicament and for use in the treatment or prevention of a viral or retroviral infection and in particular AIDS or an AIDS-related condition or Human Immunodeficiency virus (HIV).
The present invention also relates to a pharmaceutical composition comprising said quinoline derivative and to the process for preparing it as to a novel intermediate compound.

摘要翻译： 本发明涉及式（1）的喹啉衍生物或其药学上可接受的盐之一。 本发明还涉及用作药物并用于治疗或预防病毒或逆转录病毒感染，特别是AIDS或AIDS相关病症或人类免疫缺陷病毒（HIV）的喹啉衍生物。 本发明还涉及包含所述喹啉衍生物的药物组合物及其制备新型中间体化合物的方法。

公开(公告)号：EP3059591A1

公开(公告)日：2016-08-24

申请号：EP15305276.6

申请日：2015-02-23

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  Institut Curie ,  Université Montpellier

发明人： Scherrer, Didier ,  Garcel, Aude ,  Campos, Noelie ,  Vautrin, Audrey ,  Mahuteau-Betzer, Florence ,  Najman, Romain ,  Fornarelli, Pauline ,  Tazi, Jamal

IPC分类号： G01N33/569

CPC分类号： G01N33/56983 ,  G01N2333/16 ,  G01N2469/10 ,  G01N2500/02 ,  G01N2500/10

摘要： The present invention relates to a method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual, comprising at least the steps of:
a) determining the ability of a candidate compound to promote the interaction between CBP20 and CBP80 in a sample, and
b) selecting the candidate compound that is determined to promote said interaction at step a).
The present invention further relates to a method for screening a compound useful for treating or preventing a viral infection or virus-related condition in an individual, comprising at least the steps of:
a) determining the ability of a candidate compound to interact with CBP20 or CBP80 in a sample, and
b) selecting the candidate compound that is determined to interact with CBP20 or CBP80 at step a).

摘要翻译： 本发明涉及一种用于筛选用于治疗或预防病毒感染或在个体的病毒相关病症有用的化合物的方法，包括至少以下步骤：a）确定的采矿的候选化合物，以促进之间的相互作用的能力 CBP20和CBP80的样品中，和b）选择所述候选化合物确实是确定性的开采，以促进在步骤a）中所述相互作用。 本发明还涉及一种方法，用于筛选用于治疗或预防病毒感染或在单独的病毒相关病症有用的化合物，其至少包括以下步骤：a）确定的采矿的候选化合物的能力与CBP20或交互 CBP80的样品中，和b）选择所述候选化合物确实是确定性的开采在步骤a）中与CBP20或CBP80进行交互。

公开(公告)号：EP3058940A1

公开(公告)日：2016-08-24

申请号：EP15305277.4

申请日：2015-02-23

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  Institut Curie ,  Université Montpellier

发明人： Scherrer, Didier ,  Garcel, Aude ,  Campos, Noelie ,  Tazi, Jamal ,  Vautrin, Audrey ,  Mahuteau-Betzer, Florence ,  Najman, Romain ,  Fornarelli, Pauline

IPC分类号： A61K31/4709 ,  A61P31/18

CPC分类号： A61K31/47 ,  A61K31/4709 ,  A61K31/706 ,  A61K2300/00

摘要： The present invention relates to A quinoline derivative of formula (I)

or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites,
for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored.
The present invention further relates to a quinoline derivative of formula (I) as defined in claim 1, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, for which an ineffectiveness or a decline in a prior anti-retroviral treatment effectiveness has been stated and to a quinoline derivative of formula (I) as defined above, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, wherein the patient is infected by a drug-resistant viral strain, and more particularly by a drug-resistant HIV strain.

摘要翻译： 本发明涉及式（I）的喹啉衍生物或其任何其药学上可接受的盐或其任何代谢物，用于治疗或预防病毒感染，特别是HIV感染或HIV相关病症 患者; 然后在以下情况下终止所述治疗：病毒载量低或不可检测; 和/或维持或恢复CD4 +细胞计数的水平。 本发明还涉及如权利要求1所定义的式（I）喹啉衍生物或其任何药学上可接受的盐和代谢物，用于治疗或预防病毒感染，特别是HIV感染或HIV相关 已经陈述了先前的抗逆转录病毒治疗有效性的无效性或下降的患者以及上述式（I）的喹啉衍生物或其药学上可接受的盐和代谢物中的任何一种，用于 治疗或预防患者的病毒感染，特别是HIV感染或HIV相关病症，其中患者被抗药性病毒株感染，特别是耐药性HIV毒株。